Company intelligence / Profile preview

Alerpharma

Alcalá de Henares, Spain

Ownership: Private
Development stage: Other

Overview

Alerpharma, including its subsidiary Inmunal, developed and marketed commercial immunotherapy and bacteriological vaccines, notably an olive pollen vaccine highly relevant for southern Europe; acquired by Allergy Therapeutics in 2015, bringing a well-established product line and a new GMP facility.

Therapeutic areas: Immunology
Modalities: VaccineBiologic
Industry: Biotech

Beyond the preview

Go deeper on Alerpharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alerpharma.

Explore the full profile